Celtic's TDT-067 meets Phase II endpoint

Celtic (Hamilton, Bermuda) said TDT-067 met the primary endpoint of cure rate at 14 weeks in a Phase II trial to treat onychomycosis, with a 90% cure rate. The open-label study of the topical terbinaf...